-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FdjKKr6u0B3ZarO0mH10Q/prTuAApCpygcPX7DafTT3K63JmF2d5kP3IwenRDrv1 UWiYmryzmTp83PtWdnMAfw== 0001104659-07-036100.txt : 20070504 0001104659-07-036100.hdr.sgml : 20070504 20070504171251 ACCESSION NUMBER: 0001104659-07-036100 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20070504 ITEM INFORMATION: Other Events FILED AS OF DATE: 20070504 DATE AS OF CHANGE: 20070504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ISIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 07821421 BUSINESS ADDRESS: STREET 1: 1896 RUTHERFORD ROAD CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 1896 RUTHERFORD ROAD CITY: CARLSBAD STATE: CA ZIP: 92008 8-K 1 a07-13357_18k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  May 4, 2007

ISIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-19125

 

33-0336973

(Commission File No.)

 

(IRS Employer Identification No.)

 

1896 Rutherford Road
Carlsbad, CA 92008

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (760) 931-9200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



Item 8.01.              Other Events.

On May 4, 2007, Isis Pharmaceuticals, Inc. (“Isis”) announced that, because Institutional Shareholder Services (ISS) believes Isis’ consulting agreement with Dr. Richard DiMarchi that provides Dr. DiMarchi with payments of $12,000 a year does not allow ISS to consider Dr. DiMarchi an independent outside director, Isis has terminated its consulting agreement with Dr. DiMarchi.

Isis is pleased that Dr. DiMarchi will remain a valued member of Isis’ board of directors and will continue to provide Isis advice regarding Isis’ research projects and drugs in clinical development, based on Dr. DiMarchi’s over 22 years of experience in drug discovery and development, as well as perform his other duties as a director.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dated: May 4, 2007

 

By:

 

/s/ B. Lynn Parshall

 

 

 

 

B. LYNNE PARSHALL

 

 

 

 

Executive Vice President,

 

 

 

 

Chief Financial Officer and Director

 


 GRAPHIC 2 g133571bei001.gif GRAPHIC begin 644 g133571bei001.gif M1TE&.#EA"P`,`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y E!`$`````+``````+``L`@````/___P(+1(YHR>T/HYRTQ@(`.S\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----